Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 5/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21117344 | 0.84 | HIF1A (0.39) | NR1I2HIF1ALPLLIPGCA1 | |
| SCHEMBL13268591 | 0.83 | NR1I2 (0.42) | NR1I2HIF1ALPLLIPGCA1 | |
| SCHEMBL17350120 | 0.81 | LPL (0.41) | NR1I2HIF1ALPLLIPGCA1 | |
| SCHEMBL12205425 | 0.81 | LPL (0.41) | NR1I2HIF1ALPLLIPGCA1 | |
| SCHEMBL9987187 | 0.79 | AAK1 (0.33) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL23712499 | 0.79 | CA1 (0.38) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL30345334 | 0.79 | CA1 (0.38) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL20357964 | 0.74 | LPL (0.37) | NR1I2HIF1ALPLLIPGCA1 | |
| SCHEMBL23909384 | 0.74 | LPL (0.41) | NR1I2HIF1ALPLLIPGFFAR1 | |
| SCHEMBL29416738 | 0.74 | LPL (0.41) | NR1I2HIF1ALPLLIPGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140275049-A1 | SUBSTITUTED PYRAZOLE ANALOGS As RAR ANTAGONISTS | ELI LILLY AND COMPANY | 2014-09-18 | — | — | US | disclosed |
| WO-2013066640-A1 | SUBSTITUTED PYRAZOLE ANALOGUES AS RAR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275049-A1 | SUBSTITUTED PYRAZOLE ANALOGS As RAR ANTAGONISTS | RARB, RARA, RARG | NR1I2 13/4885HIF1A 1804/4885LPL 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.